Genmab A/S logo

GMAB - Genmab A/S Share Price

DKK1365.5 -9.5  -0.7%

Last Trade - 13/09/19

Sector
Healthcare
Size
Large Cap
Market Cap £10.53bn
Enterprise Value £9.73bn
Revenue £379.6m
Position in Universe 51st / 1473
Bullish
Bearish
Unlock GMAB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GMAB Revenue Unlock GMAB Revenue

Net Income

GMAB Net Income Unlock GMAB Revenue

Normalised EPS

GMAB Normalised EPS Unlock GMAB Revenue

PE Ratio Range

GMAB PE Ratio Range Unlock GMAB Revenue

Dividend Yield Range

GMAB Dividend Yield Range Unlock GMAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GMAB EPS Forecasts Unlock GMAB Revenue
Profile Summary

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated June 11, 1998
Public Since October 1, 2000
No. of Shareholders: 74,999
No. of Employees: 478
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone,
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 64,989,454
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GMAB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GMAB
Upcoming Events for GMAB
Similar to GMAB
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.